Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy.
Tryggestad AMA, Axcrona K, Axcrona U, Bigalke I, Brennhovd B, Inderberg EM, Hønnåshagen TK, Skoge LJ, Solum G, Saebøe-Larssen S, Josefsen D, Olaussen RW, Aamdal S, Skotheim RI, Myklebust TÅ, Schendel DJ, Lilleby W, Dueland S, Kvalheim G.
Tryggestad AMA, et al. Among authors: axcrona k, axcrona u.
Prostate. 2022 Feb;82(2):245-253. doi: 10.1002/pros.24267. Epub 2021 Nov 11.
Prostate. 2022.
PMID: 34762317
Clinical Trial.